drugset / Trial / NCT01452009

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

NCT01452009

Phase 3 Withdrawn Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%

Timeline

Start
2011-11
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 0.004 % Other